BEVERLY, Mass. – October 1, 2021 – LexaGene Holdings, Inc. (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or “the Company”), a commercial molecular diagnostics company selling a point-of-need, highly multiplexed in-clinic PCR system with results in approximately two hours, today announced it will be featured at three investor relations conferences in early October. LexaGene management will also participate in one-on-one meetings at each conference.
“Attending these conferences allows us to update current investors and introduce LexaGene as an investment opportunity to future investors,” said Dr. Jack Regan, LexaGene’s CEO and Founder. “The veterinary trade shows we attended in September made it clear that our technology is at the forefront of innovation and is expected to change the way diagnostics are performed in veterinary medicine. We are excited about the increasing adoption of our MiQLab™ system into more veterinary hospitals, where veterinarians are interested in providing the best possible care by utilizing the MiQLab for rapid in-clinic PCR testing for pathogens and antimicrobial resistance.”
- BioFuture 2021, October 5-6: Top innovators, investors and business leaders come together to participate in discussions that will shape and transform the future of healthcare by harnessing the power of the life sciences ecosystem and its impact on healthcare, LexaGene will provide insights into its open-access technology and the role it can play in key life science verticals. Qualified investors can request complimentary registration for the conference here.
- Lytham Partners Fall 2021 Investor Conference taking place October 5-7. Partnering with the next generation of innovators offering a diverse and effective platform for connecting small cap companies with high-quality and focused institutional investors.An audio webcast of the presentation will be made available on LexaGene’s website. To arrange a meeting, please contact a Lytham Partners representative at 1×firstname.lastname@example.org or register on their website.
- Small Cap Growth Virtual Investor Conference, October 7. A live, interactive event where investors are invited to ask companies questions in real-time. Virtual Investor Conferences is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to meet and present directly with investors. Register to attend on the Virtual Investor Conferences website.
On Behalf of the Board of Directors
Dr. Jack Regan
Chief Executive Officer & Chairman
Corporate and Media Contact:
Director of Corporate Marketing
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.